New nose spray could help diabetic eye disease when shots fail
NCT ID NCT06881888
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new nose spray version of the drug octreotide for people with diabetic macular edema, a condition that causes vision loss from fluid buildup in the eye. The trial will include 60 adults whose eye swelling has not improved with standard treatments. Researchers will measure changes in retinal thickness and vision over time to see if the spray is safe and effective.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC MACULAR EDEMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The University of Alabama at Birmingham
Birmingham, Alabama, 35243, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new eye injection preserve vision in south asians with diabetes?
- Could a biosimilar eye injection offer a new way to treat diabetic macular edema?
- Can a steroid implant boost the effect of standard eye injections for hard-to-treat diabetic macular edema?
- Eye injection aims to tame leading causes of blindness
- New eye drug aims to restore vision in Diabetes-Related swelling
- New eye drug aims to restore vision in Diabetes-Related swelling